Please ensure Javascript is enabled for purposes of website accessibility

Anti-Infective, Very Effective

By Brian Orelli, PhD - Updated Apr 6, 2017 at 9:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA seems to like Optimer's new antibiotic.

The release of briefing documents ahead of a Food and Drug Administration advisory committee meeting always adds a bit of uncertainty to a stock. It seems Optimer Pharmaceuticals' (Nasdaq: OPTR) investors had little to worry about for tomorrow's meeting of the Anti-Infective Drugs Advisory Committee. After the documents for committee members were released Friday, shares shot up 11%.

That seems about right. The FDA concluded that Optimer's fidaxomicin is as effective as ViroPharma's (Nasdaq: VPHM) Vancocin in curing infections, and is superior to Vancocin at preventing recurrences.

An approval of fidaxomicin will almost certainly have an effect on Vancocin's sales, but it'll have a marginal effect of ViroPharma's valuation. Investors have priced in expected generic competition, and ViroPharma has become less reliant on Vancocin since the launch of Cinryze.

If generic versions of Vancocin eventually make it to market, I don't think it'll affect sales of fidaxomicin much. The antibiotic doesn't have to be taken for that long, so the difference in the price of copays isn't as big of a deal as it is for something like cholesterol drugs, which have to be taken long term. Generic versions of Merck's (NYSE: MRK) Zocor indirectly affect Pfizer's (NYSE: PFE) Lipitor and AstraZeneca's (NYSE: AZN) Crestor because patients prefer the lower copay for generics available under many insurance plans.

There's a human element to advisory committee meetings, which means Optimer isn't completely out of the woods yet. One expert on the panel might have an axe to grind, or just latch onto one piece of safety data without looking at the larger picture. But the general upbeat tone of the briefing documents should give investors confidence that a unanimously positive recommendation isn't required for the FDA to sign off on the drug. I'd guess a 5-2 vote recommending approval should be enough to gain approval from the agency next month.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.42 (1.37%) $1.25
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.95 (-0.18%) $0.12
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.